Swiss Pharma Giant Roche to Acquire Telavant Holdings in $7.1B Deal
By
Darya Rudz
As a result of the $7.1 billion transaction, Roche will get the rights to develop and distribute RVT-3101 in the US and Japan. The deal is expected to be completed at the end of this year or in the first quarter of 2024.